title: Stability of infectious human coronavirus NL63.
abstract: The human coronavirus NL63 was identified in 2004 and subsequent studies showed its worldwide distribution. Infection with this pathogen is associated with upper and lower respiratory tract diseases of mild to moderate severity. Furthermore, HCoV-NL63 is the main cause of croup in children. Within this study an optimal protocol for freeze-drying that allows safe and effective preservation of HCoV-NL63 infectious material was developed. Lyophilized virus preparations can be stored either at ambient temperature or at +4°C. In the latter case samples may be stored for at least two months. Surprisingly, conducted analysis showed that HCoV-NL63 virions are exquisitely stable in liquid media and can be stored also without preservatives at ambient temperature for up to 14 days.
authors.affiliation: Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland.
authors.forename: Dominik
authors.initials: D
authors.lastname: Florek
authors.affiliation: Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland.
authors.forename: Michal
authors.initials: M
authors.lastname: Burmistrz
authors.affiliation: Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland; Oral Health and Systemic Disease Research Group, School of Dentistry, University of Louisville, Louisville, KY, USA.
authors.forename: Jan
authors.initials: J
authors.lastname: Potempa
authors.affiliation: Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland; Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland. Electronic address: k.a.pyrc@uj.edu.pl.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Pyrc
mesh_terms: D018352:Coronavirus Infections / Q000821:virology*; D058957:Coronavirus NL63, Human / Q000502:physiology*; D005612:Freeze Drying; D006801:Humans; D014771:Virion
keywords: Coronaviridae; Coronavirus; HCoV-NL63; Lyophilization; NL63; Stability
references.citation: Pediatr Infect Dis J. 2010 Sep;29(9):822-6
references.pmid: 20720471
references.citation: J Control Release. 2010 Nov 20;148(1):e108-10
references.pmid: 21529580
references.citation: Pharm Dev Technol. 1998 Aug;3(3):373-83
references.pmid: 9742558
references.citation: J Gen Virol. 2010 Jun;91(Pt 6):1450-60
references.pmid: 20147516
references.citation: Jpn J Infect Dis. 2012;65(3):270-2
references.pmid: 22627314
references.citation: J Mol Biol. 2006 Dec 15;364(5):964-73
references.pmid: 17054987
references.citation: J Virol. 2010 Nov;84(21):11255-63
references.pmid: 20719951
references.citation: Dev Biol Stand. 1976 Oct;36:297-303
references.pmid: 1030428
references.citation: J Clin Microbiol. 1980 Oct;12(4):483-9
references.pmid: 6252243
references.citation: Can J Microbiol. 1989 Oct;35(10):972-4
references.pmid: 2819602
references.citation: Viruses. 2010 Aug;2(8):1804-20
references.pmid: 21994708
references.citation: N Engl J Med. 2003 May 15;348(20):1953-66
references.pmid: 12690092
references.citation: J Virol Methods. 1982 Nov;5(3-4):165-71
references.pmid: 6296178
references.citation: J Infect Dis. 2005 Feb 15;191(4):503-6
references.pmid: 15655772
references.citation: Drug Dev Ind Pharm. 2009 Jan;35(1):83-97
references.pmid: 19016059
references.citation: MMWR Morb Mortal Wkly Rep. 2013 Sep 27;62(38):793-6
references.pmid: 24067584
references.citation: Pharm Res. 2008 Jun;25(6):1256-73
references.pmid: 18338241
references.citation: N Engl J Med. 2012 Nov 8;367(19):1814-20
references.pmid: 23075143
references.citation: Poult Sci. 2010 Jun;89(6):1167-70
references.pmid: 20460663
references.citation: J Clin Microbiol. 2010 Aug;48(8):2940-7
references.pmid: 20554810
references.citation: J Virol Methods. 2002 Apr;102(1-2):15-25
references.pmid: 11879689
references.citation: Eur J Pharm Sci. 2007 Sep;32(1):33-44
references.pmid: 17628452
references.citation: N Engl J Med. 2003 May 15;348(20):1967-76
references.pmid: 12690091
references.citation: PLoS Med. 2005 Aug;2(8):e240
references.pmid: 16104827
references.citation: J Virol Methods. 2006 Dec;138(1-2):207-10
references.pmid: 16962670
references.citation: J Hosp Infect. 2008 Aug;69(4):406-8
references.pmid: 18541340
references.citation: J Aerosol Med Pulm Drug Deliv. 2008 Mar;21(1):25-34
references.pmid: 18518829
references.citation: J Gen Virol. 1982 Nov;63 (Pt 1):241-5
references.pmid: 6890987
references.citation: Nat Med. 2004 Apr;10(4):368-73
references.pmid: 15034574
references.citation: J Virol. 2005 Jan;79(2):884-95
references.pmid: 15613317
references.citation: Vaccine. 2011 Jun 10;29(26):4345-52
references.pmid: 21514345
references.citation: AAPS J. 2010 Jun;12(2):215-22
references.pmid: 20195930
references.citation: J Virol. 2007 Apr;81(7):3051-7
references.pmid: 17079323
references.citation: Biotechnol Prog. 1998 Jul-Aug;14(4):615-20
references.pmid: 9694684
references.citation: J Parenter Sci Technol. 1988 Nov-Dec;42(6):190-9
references.pmid: 3221279
references.citation: BMC Infect Dis. 2005 Feb 01;5:6
references.pmid: 15686594
references.citation: Mem Inst Oswaldo Cruz. 2012 Aug;107(5):693-4
references.pmid: 22850964
references.citation: Lancet. 2003 Apr 19;361(9366):1319-25
references.pmid: 12711465